NF2 Therapeutic Composition Targeting TβR1-Mediated RKIP Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurofibromatosis type 2 (NF2) syndrome, such as TEW7197, inhibit TGF-β signaling, leading to adverse effects due to its importance in normal homeostasis and development, necessitating a compound that inhibits TβR1-mediated RKIP reduction without interfering with normal TGF-β signaling.
Innovation Solution
A novel compound, represented by Chemical Formula 1, inhibits TβR1-mediated RKIP reduction without affecting normal TGF-β signaling, promoting differentiation of schwann cells and inhibiting tumor growth in NF2 syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TEW7197 is used to inhibit TβR1 kinase activity, then schwannoma growth is suppressed, but normal TGF-β signaling is interfered with causing adverse effects
Solution Approach 1:
The patent segments the TGF-β signaling pathway inhibition into a specific target (TβR1-RKIP interaction) rather than broad TGF-β pathway inhibition. The compound selectively blocks TβR1-mediated RKIP reduction while allowing other TGF-β signaling functions to proceed normally, thus achieving therapeutic efficacy without systemic adverse effects.
Solution Approach 2:
The compound acts as an intermediary substance that specifically interferes with the TβR1-RKIP interaction. Rather than directly inhibiting TβR1 kinase activity broadly, it mediates a selective block of RKIP reduction, preserving normal TGF-β signaling while achieving anti-schwannoma effects.
2Reliability
If broad TGF-β signaling inhibition is applied, then tumor growth is suppressed, but normal homeostasis and development are disrupted
Solution Approach 1:
The compound exhibits local quality by selectively targeting the TβR1-RKIP interaction specifically in schwannoma cells where NF2 is mutated, while sparing normal tissues that rely on TGF-β signaling for homeostasis and development. This localized action achieves tumor suppression without disrupting normal physiological processes.
Solution Approach 2:
The compound changes the specific parameter of RKIP stability in schwannoma cells by blocking TβR1-mediated RKIP reduction, rather than changing broad TGF-β signaling parameters. This selective parameter change achieves therapeutic effect while preserving normal physiological parameters.
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to a composition for prevention or treatment of neurofibromatosis type 2 syndrome. In contrast to the conventional TβR1 kinase inhibitor TEW7197, the compound represented by chemical formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, or a combination thereof according to the present invention suppresses TGF-β receptor 1 (TβR1)-mediated RKIP reduction while not inhibiting normal TGF-β signaling and thus, can be used as a novel form of a therapeutic agent for neurofibromatosis type 2 syndrome, which can solve the side effect problem caused by the inhibition of normal TGF-β signaling.